Unleashing Platform-Level Innovation Capabilities in Antiserum Development | Jiangxi Bio Invited to Attend the Jiangxi Provincial Symposium on the Development of the Future Biopharmaceutical Industry

Preface:

On March 31, 2026, Yin Hong, Secretary of the Jiangxi Provincial Party Committee, chaired a symposium on the development of the future bio–biopharmaceutical industry. Jiangxi Bio, as a key biopharmaceutical enterprise in Jiangxi Province, was invited to attend and engaged in discussions on industry development alongside leading companies such as Renhe Group and China Resources Jiangzhong.

As a biopharmaceutical company with more than 50 years of deep expertise in the antiserum field, the company is leveraging “technology + end-to-end industrial chain + pilot-scale platform translation” to accelerate the full realization of its antiserum platform capabilities, strategically position itself in mRNA synthetic biology–driven novel antibody R&D, tackle cutting-edge core technologies, and swiftly build competitive advantages in niche biopharmaceutical segments—thereby contributing the company’s strength to the development of Jiangxi’s “Future Biotech” industry.

Source: National-level Jinggangshan Economic Development Zone 
On March 31, Yin Hong, Secretary of the Provincial Party Committee, chaired a symposium on the development of the future bio–biopharmaceutical industry. The Jiangxi Institute of Biological Products Co., Ltd. (referred to as “Jiangxi Bio”), based in the Jinggangshan Economic and Technological Development Zone, was invited to attend the meeting and joined leading enterprises such as Renhe Group and China Resources Jiangzhong in voicing their views.

As an industry giant with more than 50 years of deep expertise in the antiserum field, Jiangxi Bio is accelerating its pace in the biopharmaceutical niche market through its robust “technology + full-industry-chain” capabilities.

Hardcore Capabilities: Three “Uniques” Define Industry Standards

In 2025, Jiangxi Bio is set to launch a groundbreaking new-generation tetanus antitoxin (TAT), redefining industry standards through “three unique” technological breakthroughs:

• The only product in China packaged in vials, which prevents active ingredient degradation and ensures greater safety and efficacy.
• The only domestically developed technology for implanting and removing/inactivating BVD virus, ensuring maximum safety;
• The only TAT product in China that contains no preservatives, reducing the incidence of adverse reactions to 0.03%, well below the industry average.

Data show that the product’s specific activity reaches as high as 80,000 IU/g, nearly twice the national standard, thereby safeguarding the lives and safety of hundreds of millions of patients with traumatic injuries.

Global Landscape: Dominant Player Across the Entire Industrial Chain, Leading the World with a Clear Competitive Edge 
It’s not just the technology—Jiangxi Bio’s industry scale and global standing are equally impressive:

• It is the world’s largest supplier of human tetanus antitoxin, with a 65.8% market share in China in 2024 and a global share exceeding 36.6%.
• Boasting China’s largest GMP-compliant horse-breeding facility, with an annual plasma output exceeding 100 million milliliters, we ensure global supply from the very source.
• The product portfolio covers more than 27,000 medical institutions, including over 1,500 tertiary hospitals, and is included in the National Class-A Medical Insurance Catalog, the Essential Medicines List, and the Emergency Rescue Medicines List, with full reimbursement under national medical insurance.
• Moreover, it is the world’s only company that develops antisera using recombinant proteins, mRNA, and serum-free antigens, with technological capabilities on par with the global elite.

Innovation Engine: A Pilot-Scale Platform to Bridge the “Valley of Death”

The symposium emphasized: “We must strengthen the foundation of scientific and technological innovation, reinforce the central role of enterprises in innovation, and support them in establishing R&D centers, pilot-scale testing facilities, and concept-validation centers.” Jiangxi Bio’s achievement is the province’s first pilot-scale platform for biologic immune antibody drugs.

• This “innovation accelerator,” which has received nearly RMB 30 million in investment, has successfully bridged the “valley of death” that separates laboratory research from industrial production.
• Possesses end-to-end modular pilot-scale capabilities, reducing the R&D cycle by an average of 40%;
• Secure two national clinical trial approvals and one vial-based TAT production license within 2025.
• By introducing digital twin technology, we will build a smart R&D system that is “visible, optimizable, and predictable,” thereby fostering an innovation “rainforest” with Ji’an’s distinctive characteristics.

Jingkai’s Commitment: Anchoring the Future, Empowering Industrial Clusters

Jiangxi Bio is not only a leader but also an incubator. By opening up its pilot-scale testing platform and facilitating connections with government and enterprise resources, it is driving coordinated development across the upstream and downstream segments of the biopharmaceutical industry chain in the Jinggangshan Economic Development Zone.

Looking ahead, Jiangxi Bio will continue to deepen its expertise in the antiserum field, with a strategic focus on mRNA synthetic biology–driven next-generation antibody R&D. The company will also tackle cutting-edge, future-oriented key technologies, including LNP lipid delivery, high-purity F(ab')₂ preparation, microsphere sustained-release systems, and human-derived organoid-based evaluation. By breaking the industry’s “chokehold” bottlenecks, we will steadfastly build a product pipeline that features “one generation in production, one in R&D, and one in reserve,” leveraging the sense of responsibility of Ji’an enterprises to inject strong momentum into the high-quality development of Jiangxi’s “future bio” industry and deliver a safer, more effective “Chinese solution.” 。